By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is bearish on QBTS (D-Wave) due to high cash burn, unproven commercial scalability, and uncertainty around CHIPS Act funding allocation. The recent rally is driven by speculative fervor and retail momentum rather than fundamentals.
Risk: High cash burn and uncertainty around CHIPS Act funding allocation could force dilution and amplify downside from the current $27 level.
Opportunity: Securing a significant portion of the federal funding could provide a temporary catalyst for the stock.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
D-Wave Quantum Inc. shares were active in after-hours trading Friday .
QBTS shares jumped 7.81% to $27.75 in after-hours trading after closing the regular session up 33.37% at $25.74.
Company executive Sophie Ames disclosed the sale of 23,025 shares in a newly filed Securities and Exchange Commission Form 4 amid continued momentum in quantum computing stocks following reports of potential CHIPS Act funding for the sector.
D-Wave develops commercial quantum computing systems, software and services focused on optimization and enterprise applications.
Ames, D-Wave's Executive Vice President and Chief Human Resources Officer, sold approximately $437,000 worth of shares on May 20 at a weighted average price of about $18.98.
The filing showed the transactions were executed under a pre-arranged Rule 10b5-1 trading plan that was adopted in June 2025 and later modified in September 2025.
The shares were sold in multiple transactions ranging from $18.35 to $19.40, according to the filing.
Following the sale, Ames continued to hold 596,803 shares, including 543,750 unvested restricted stock units.
CHIPS Funding
Investor attention also remained focused on reports that the Trump administration plans to award roughly $2 billion to companies in the quantum computing sector under the CHIPS and Science Act.
Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment. That's why many investors look to diversify with platforms that provide access to real estate, fixed-income opportunities, professional financial guidance, precious metals, and even self-directed retirement accounts. By spreading exposure across multiple asset classes, it becomes easier to manage risk, capture steady returns, and create long-term wealth that isn't tied to the fortunes of just one company or industry.
Backed by institutions including NASA and the NIH, rHealth is targeting the large global diagnostics market with a multi-test platform and a model built around devices, consumables, and software. With FDA registration in progress, the company is positioning itself as a potential shift toward faster, more decentralized healthcare testing.
Masterworks enables investors to diversify into blue-chip art, an alternative asset class with historically low correlation to stocks and bonds. Through fractional ownership of museum-quality works by artists like Banksy, Basquiat, and Picasso, investors gain access without the high costs or complexities of owning art outright. With hundreds of offerings and strong historical exits on select works, Masterworks adds a scarce, globally traded asset to portfolios seeking long-term diversification.
Accredited Debt Relief is a debt consolidation company focused on helping consumers reduce and manage unsecured debt through structured programs and personalized solutions. Having supported more than 1 million clients and helped resolve over $3 billion in debt, the company operates within the growing consumer debt relief industry, where demand continues to rise alongside record household debt levels. Its process includes a quick qualification survey, personalized program matching, and ongoing support, with eligible clients potentially reducing monthly payments by 40% or more. With industry recognition, an A+ BBB rating, and multiple customer service awards, Accredited Debt Relief positions itself as a data-driven, client-focused option for individuals seeking a more manageable path toward becoming debt-free.
Four leading AI models discuss this article
"Pre-planned insider selling plus unconfirmed funding leaves QBTS vulnerable to sharp reversal despite the headline-driven spike."
QBTS surged 33% on CHIPS Act speculation, yet the EVP sale of 23k shares at $18.98 via a 2025 10b5-1 plan still flags caution. The plan predates the rally, but execution near recent lows suggests limited conviction even as shares hit $25.74 after-hours. Quantum funding talk remains early-stage with no firm allocation timeline, while D-Wave's commercial traction stays narrow. Volatility around policy headlines can reverse fast if appropriations stall or broader tech rotation hits. The promotional filler in the article further dilutes credibility of the momentum narrative.
The pre-arranged plan removes any fresh negative signal from Ames, and a $2B quantum allocation under CHIPS could still catalyze re-rating if confirmed in coming quarters.
"A 33% single-day rally on unconfirmed CHIPS Act rumors, coupled with an insider selling at 32% below current price, suggests momentum-driven speculation rather than fundamental re-rating."
The article conflates two unrelated events: Ames' pre-planned share sale (executed under a Rule 10b5-1 plan adopted June 2025, modified September 2025) and QBTS' 33% single-day rally. The sale itself is bearish signal—an insider liquidating ~$437k at $18.98 while stock now trades $27.75 suggests she sold well below current momentum. However, the $2B CHIPS Act quantum funding rumor is the actual driver. The problem: no confirmation this funding exists or that D-Wave qualifies. The article provides zero detail on allocation criteria, timeline, or competitive landscape. Ames retains 596k shares (543k unvested), so she's not abandoning conviction entirely.
Rule 10b5-1 plans are legally binding and pre-arranged specifically to avoid insider trading accusations—her sale timing proves nothing about her confidence. The real story is the CHIPS funding rumor, which could be real and material, making the insider sale irrelevant noise.
"QBTS is currently a momentum-driven play that lacks the fundamental earnings support to justify a 33% move, making it highly vulnerable to a 'sell the news' crash if federal funding is less than anticipated."
The 33% single-session jump in D-Wave (QBTS) is driven by speculative fervor surrounding the $2 billion CHIPS Act allocation, not fundamental breakthroughs. While the executive sale of $437,000 via a 10b5-1 plan is technically routine, the timing is opportunistic given the massive volatility. Investors are front-running potential government subsidies, but D-Wave’s financials remain precarious with high cash burn and unproven commercial scalability. The stock is currently trading on sentiment and retail momentum rather than discounted cash flow. Unless the company secures a significant portion of that federal funding, the current valuation is disconnected from the reality of its long-term path to profitability.
The 10b5-1 plan was established months ago, suggesting this sale was a pre-planned liquidity event rather than a signal of internal pessimism regarding the CHIPS Act upside.
"The news is largely sentiment-driven and the insider sale is likely not a meaningful signal; near-term upside depends on uncertain funding and sector momentum, not clear fundamentals."
QBTS's after-hours move appears driven by sector sentiment around quantum computing rather than a clear fundamental upgrade at D-Wave. The insider sale by Sophie Ames totals about $437k and is disclosed under a pre-planned 10b5-1, which is common and often non-informative about a company's trajectory. The CHIPS Act funding chatter could provide a temporary catalysts, but quantum commercialization remains uncertain with long product cycles and profitability risk for D-Wave's hardware. The article's promotional interludes on diversification dilute objectivity. Key risks include execution, customer concentration, and the speculative nature of quantum-technology paths; any upside hinges more on sentiment than transparent earnings catalysts.
Devil's advocate: Even though the sale is small, it could be construed as a caution signal about near-term visibility; the rally may fade if sector enthusiasm cools or CHIPS funding timelines shift.
"The September modification to the 10b5-1 plan undercuts claims that the insider sale carries no informational content."
Claude highlights the September 2025 modification to Ames' 10b5-1 plan yet dismisses its signaling value. That update occurred well after initial CHIPS speculation surfaced, allowing her to adjust sale parameters amid rising volatility. This timing weakens the 'pre-arranged and irrelevant' defense across the panel. If funding timelines slip beyond 2026, QBTS's cash burn could force dilution before any allocation materializes, amplifying downside from the current $27 level.
"The September plan modification signals tactical liquidity needs, not strategic doubt—but D-Wave's cash burn timeline vs. CHIPS disbursement lag is the actual cliff risk nobody quantified."
Grok's point on the September 2025 modification is sharp—that's not routine housekeeping, that's a parameter tweak mid-rally. But we're conflating two separate signals: adjusting sale *terms* doesn't prove pessimism about CHIPS funding; it proves she wanted liquidity *then*, not later. The real gap: nobody's quantified D-Wave's cash runway. If burn is $40M+ annually and CHIPS allocation takes 18+ months, dilution risk is material regardless of insider conviction.
"The stock's valuation is disconnected from commercial reality, and CHIPS funding will likely be insufficient to justify current price levels."
Claude and Grok are obsessing over the 10b5-1 modification, but they are missing the forest for the trees. The real risk isn't insider liquidity; it's the structural mismatch between D-Wave's current $1B+ market cap and its revenue profile. Even if the $2B CHIPS funding materializes, it will be spread across multiple players. D-Wave's commercial backlog is stagnant, and the current valuation assumes full-scale adoption that is still years away. The rally is pure retail-driven gamma.
"The dilution risk from delayed CHIPS funding and ongoing cash burn makes QBTS's current valuation fragile, regardless of insider-sale mechanics or speculative subsidies."
Claude's defense of the 10b5-1 tweak misses a larger structural risk: even if the CHIPS funds materialize, D-Wave still faces a burn-rate cliff and potential dilution long before any subsidies arrive. With a >$1B market cap and a cloud of uncertainty around allocation timing and beneficiaries, the stock's surge is a function of sentiment rather than near-term cash flow visibility. Until there’s credible milestones or a binding funding timetable, valuation remains precarious.
The panel consensus is bearish on QBTS (D-Wave) due to high cash burn, unproven commercial scalability, and uncertainty around CHIPS Act funding allocation. The recent rally is driven by speculative fervor and retail momentum rather than fundamentals.
Securing a significant portion of the federal funding could provide a temporary catalyst for the stock.
High cash burn and uncertainty around CHIPS Act funding allocation could force dilution and amplify downside from the current $27 level.